Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome–an insidious disease: The recent COVID-19 pandemic has brought substantial attention to the overlapping symptoms between long COVID and myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS), a chronic and poorly understood neurological disorder (Shankar et al., 2024). The prevalence of ME/CFS is estimated to be over 2 million in the United States (No authors listed, 2015). People with ME/CFS often report prolonged fatigue, chronic or intermittent pain syndromes, autonomic abnormalities, post-exertional malaise, cognitive impairment, and reduced quality of life over an enduring period, many of which do not fully recover from this clinical condition (No authors listed, 2015). Furthermore, the condition is marked by considerable heterogeneity in its clinical definitions and the absence of a definitive diagnostic test, complicating both diagnosis and treatment. Because physicians often struggle to recognize the condition of ME/CFS and form a diagnosis, many individuals are never diagnosed hence the actual number would be substantially higher, posing additional complexity in developing evidence-based therapies for ME/CFS.